Japan includes a huge market for biopharmaceutical products which is open for innovative products and services, also those from abroad. Current trends are in immunotherapeuticals, cell-based products and genomic medicine. Japanese regulations favour innovative products and services and thus may offer an opportunity for fast-track market access. In view of specific rules and regulations, however, it may be advantageous for European SMEs to team up with Japanese or international marketing authorisation holders (MAHs).
The webinar is targeted to EU companies seeking to export their innovative biopharmaceutical products or services to Japan .
Registration deadline: 16/10/2019
In 40 minutes from your desk, you will discover how to:
Speaker: Rolf Schmid - Bio4Business
Moderator: Gwenael Beauvais - Business Support Coordinator, EU-Japan Centre for Industrial Cooperation
Organiser: EU-Japan Centre for Industrial Cooperation - Brussels Office
Various EU products and services began to enjoy benefits from the EU-Japan Economic Partnership Agreement (EPA) which entered in force on 1 February 2019, and we are seeing a considerable increase of
This website and related activities are managed by the EU-Japan Centre for Industrial Cooperation, a joint venture between the European Commission's Directorate-General for Internal Market, Industry, Entrepreneurship and SMEs (DG GROW) and the Japanese Government's Ministry of Economy, Trade & Industry (METI).
Hundreds of web pages with up-to-date information on Japan, more than 400 market reports and recorded webinars available as well as a lot of detailed information on Japanese business culture.